Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice
Open Access
- 16 January 2008
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (2) , 295-302
- https://doi.org/10.2967/jnumed.107.046888
Abstract
The aim of this study was to determine if pulsed high-intensity focused ultrasound (HIFU) exposures could enhance tumor uptake of 111In-MX-B3, a murine IgG1κ monoclonal antibody directed against the Ley antigen. Methods: MX-B3 was labeled with 111In, purified, and confirmed for its binding to the antigen-positive A431 cell line. Groups of nude mice were inoculated subcutaneously with A431 tumor cells on both hind flanks. A tumor on one flank was treated with pulsed-HIFU; the other tumor was used as an untreated control. Within 10 min after the HIFU exposure, the mice received intravenous 111In-MX-B3 for imaging and biodistribution studies. Mice were euthanized at 1, 24, 48, and 120 h after injection for biodistribution studies. Results: The HIFU exposure shortened the peak tumor uptake time (24 vs. 48 h for the control) and increased the peak tumor uptake value (38 vs. 25 %ID/g [percentage injected dose per gram] for the control). The HIFU effect on enhancing tumor uptake was greater at earlier times up to 24 h, but the effect was gradually diminished thereafter. The HIFU effect on enhancing tumor uptake was substantiated by nuclear imaging studies. HIFU also increased the uptake of the antibody in surrounding tissues, but the net increase was marginal compared with the increase in tumor uptake. Conclusion: This study demonstrates that pulsed-HIFU significantly enhances the delivery of 111In-MX-B3 in human epidermoid tumors xenografted in nude mice. The results of this pilot study warrant further evaluation of other treatment regimens, such as repeated HIFU exposures for greater delivery enhancement of antibodies labeled with cytotoxic radioisotopes or pulsed-HIFU exposure in addition to a combined therapy of 90Y-B3 and taxol to enhance the synergistic effect.Keywords
This publication has 31 references indexed in Scilit:
- Bevacizumab in the treatment of colorectal cancerExpert Opinion on Biological Therapy, 2007
- The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR AgentsMolecular Cancer Research, 2007
- Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their ModulationClinical Cancer Research, 2007
- Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv DimersClinical Cancer Research, 2006
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2001
- Monoclonal Antibody Therapy in Lymphoid MalignanciesThe Oncologist, 2000
- Monoclonal antibody therapy for solid tumorsCancer Treatment Reviews, 2000
- Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac [see comments]Blood, 1995
- Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.Proceedings of the National Academy of Sciences, 1995